Article

P193 USEFUL I: musculoskeletal ultrasound to identify patients with lupus arthritis with better response to therapy

Mahmoud, Khaled, Zayat, Ahmed S, Yusof, Md Yuzailful Md, Dutton, Katherine, Teh, Lee Suan, Yee, Chee-Seng, D’Cruz, David, Ng, Nora, Isenberg, David, Ciurtin, Coziana and Et, Al

Available at http://clok.uclan.ac.uk/32821/

Mahmoud, Khaled, Zayat, Ahmed S, Yusof, Md Yuzailful Md, Dutton, Katherine, Teh, Lee Suan, Yee, Chee-Seng, D’Cruz, David, Ng, Nora, Isenberg, David et al (2020) P193 USEFUL I: musculoskeletal ultrasound to identify patients with lupus arthritis with better response to therapy. Lupus Science & Medicine, 7.

It is advisable to refer to the publisher’s version if you intend to cite from the work. http://dx.doi.org/10.1136/lupus-2020-eurolupus.235

For more information about UCLan’s research in this area go to http://www.uclan.ac.uk/researchgroups/ and search for <name of research Group>.

For information about Research generally at UCLan please go to http://www.uclan.ac.uk/research/

All outputs in CLoK are protected by Intellectual Property Rights law, including Copyright law. Copyright, IPR and Moral Rights for the works on this site are retained by the individual authors and/or other copyright owners. Terms and conditions for use of this material are defined in the http://clok.uclan.ac.uk/policies/
**USEFUL I: MUSCULOSKELETAL ULTRASOUND TO IDENTIFY PATIENTS WITH LUPUS ARTHRITIS WITH BETTER RESPONSE TO THERAPY**

1,2Khaled Mahmoud, 3Ahmed S Zayat, 1,2Md Yusuf Md Yusof, 1,2Katherine Dutton, 4Lee Suan Teh, 5Chee-Seng Yee, 6David D’Cruz, 7Nora Ng, 8David Isenberg, 7Coziana Ciurtin, 1,2Philip Conaghan, 2Paul Emery, 3Chris Edwards, 1,2Elizabeth MA Hensor, 1,2Edward M Vital. 1NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds; 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; 3Bradford Teaching Hospitals NHS Foundation Trust, Bradford; 4Royal Blackburn Teaching Hospital, Blackburn and University of Central Lancashire, Preston; 5Doncaster and Bassetlaw NHS Trust, Doncaster; 6Guys and St Thomas Hospital, London; 7University College London, London; 8University Hospital Southampton NHS Foundation Trust, Southampton

**Background**

In SLE, musculoskeletal manifestations have an impact on quality of life, disability and clinical trial outcomes, but are harder to assess than in RA and PsA. We previously showed that joint swelling lacks sensitivity, specificity and responsiveness compared to ultrasound. USEFUL was a multi-centre longitudinal study to determine clinical features predicting ultrasound synovitis and whether patients with ultrasound synovitis respond better to therapy.

**Methods**

SLE patients were recruited if the referring physician deemed they had inflammatory pain warranting treatment. Swollen joints were not required. At baseline, physicians recorded the features that led them to diagnose inflammatory pain and features of concurrent fibromyalgia and osteoarthritis. Stable doses of prednisolone (<5 mg/day), antimalarials or immunosuppressants were allowed. Participants received depotmedrone 120 mg IM then were assessed at 0, 2 and 6 weeks for 66/68 swollen and tender joint counts, BILAG-2004, SLE-DAI-2K, physician global and MSK-VAS, inflammatory markers, patient pain and disease activity-VAS, HAQ-DI, LupusQoL, ultrasound of hands and wrists (blinded to patient and clinical assessor). An internal pilot determined the primary endpoint: EMS-VAS at 2 weeks (adjusted for baseline) between patients with ultrasound-synovitis vs. normal ultrasound at baseline. Sensitivity analyses adjusted for prednisolone and immunosuppressants.

**Results**

122/133 patients recruited completed all visits. There was significant disagreement between clinical examination and ultrasound. 78/133 had ultrasound synovitis; 68% of these had >1 swollen joint. Of 66/133 patients with >1 swollen joint, 20% had normal ultrasound.

Ultrasound-synovitis was more likely with joint swelling, a symmetrical small joint distribution and active serology. Physician-determined EMS, other lupus features or prior response to therapy were not associated. Fibromyalgia or osteoarthritis did not reduce the probability of ultrasound synovitis.

In the full analysis set (n=133) there was no difference in EMS VAS at 2 weeks according to ultrasound synovial status as baseline (difference -8 mm, 95% CI -19, 4 mm, p=0.178). 32 patients had fibromyalgia. After excluding these patients, we found a statistically and clinically significantly better clinical response to depotmedrone in patients with ultrasound-synovitis at baseline (baseline-adjusted EMS VAS at 2 weeks -12 mm, 95% CI -24, 0 mm, p=0.049). This difference was greater in the treatment-adjusted sensitivity analysis (-12.8 (95% CI -22, -3 mm), p=0.007) and the per-protocol-adjusted sensitivity analysis (-14.8 mm (95% CI -20.8, -8.8 mm), p<0.001). Patient with ultrasound synovitis had higher rates of improvement in the musculoskeletal BILAG-2004 (56% vs. 26%, p=0.09) and SLE-DAI-2K (37% vs. 15%, p=0.03).

**Conclusions**

In lupus arthritis distribution and serology, but not other features, help identify ultrasound-synovitis. Ultrasound-synovitis was independent of features of fibromyalgia, but fibromyalgia confounded assessment of response. Excluding fibromyalgia, response to therapy was better in patients with abnormal ultrasound compared to normal. Ultrasound should be used to select patients for therapy and clinical trials, especially when there are inflammatory symptoms without swollen joints.

**Acknowledgements**

This project was funded by a grant from Lupus UK.